IP Library Granted Patent US 10,180,432
Granted Patent B2
US 10,180,432 · App. 15/620,117 · Granted Jan 15, 2019

Diagnostic assays and kits for detection of folate receptor 1

Inventors: Christina N. Carrigan (Belmont, MA); Olga Ab (Millis, MA); Daniel Tavares (Natick, MA); Beni B. Wolf (Lexington, MA)
Assignee: ImmunoGen, inc.
G01N33/57492A61K47/6849C07K16/28C07K16/30C07K16/303C07K16/3015C07K16/3023C07K16/3069G01N33/566C07K2317/21C07K2317/24C07K2317/33C07K2317/76C07K2317/92G01N2333/705
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,180,432
App. No.
15/620,117
Granted
Jan 15, 2019
Kind
B2
Abstract

The invention generally relates to antibodies that bind to human folate receptor 1 and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.

Claims (18)

1. A nucleic acid molecule comprising a polynucleotide sequence encoding an antibody or antigen-binding fragment thereof that specifically binds to FOLR1 and comprises variable heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOS:1, 2, and 3, respectively, and variable light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOS:13, 14, an 15, respectively.

2. A vector comprising the nucleic acid molecule of claim 1 .

3. The vector of claim 2 , wherein said vector further comprises a promoter binding site and optionally an enhancer sequence.

4. The vector of claim 2 , wherein said vector is a plasmid, a virus, a phage, a bacterium or a viroid.

5. A cell producing an antibody or antigen-binding fragment thereof encoded by the nucleic acid molecule of claim 1 .

6. The cell of claim 5 , wherein said cell is a bacterial cell or a eukaryotic cell.

7. A method of making an antibody or antigen-binding fragment thereof, comprising (a) culturing the cell of claim 5 ; and (b) isolating the antibody or antigen-binding fragment thereof from said cultured cell.

8. The nucleic acid molecule of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises the variable heavy chain (VH) polypeptide of SEQ ID NO:25 and the variable light chain (VL) polypeptide of SEQ ID NO:29.

9. The nucleic acid molecule of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises the full-length heavy chain polypeptide of SEQ ID NO:33 and the full-length light chain polypeptide of SEQ ID NO:37.

10. The nucleic acid molecule of claim 1 , wherein the antibody or antigen-binding fragment thereof is non-human, humanized, chimeric, or resurfaced.

11. The nucleic acid molecule of claim 1 , wherein the antibody or antigen-binding fragment thereof is a full length antibody.

12. The nucleic acid molecule of claim 1 , wherein the antibody or antigen-binding fragment thereof is an antigen-binding fragment.

13. The nucleic acid molecule of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a Fab, Fab′, F(ab′)2, Fd, single chain Fv or scFv, disulfide linked Fv, V-NAR domain, IgNar, intrabody, IgGΔCH2, minibody, F(ab′)3, tetrabody, triabody, diabody, single-domain antibody, DVD-Ig, Fcab, mAb2, (scFv)2, or scFv-Fc.

14. The nucleic acid molecule of claim 1 , wherein the antibody or antigen-binding fragment thereof binds to a human FOLR1 with a Kd of about 1.0 nM to about 10 nM.

15. A nucleic acid molecule comprising a polynucleotide sequence encoding a polypeptide comprising SEQ ID NO:25.

16. A nucleic acid molecule comprising a polynucleotide sequence encoding a polypeptide comprising SEQ ID NO:29.

17. A cell comprising the nucleic acid molecule of claim 15 ;

further comprising a second nucleic acid molecule comprising a polynucleotide sequence encoding a polypeptide comprising SEQ ID NO:29.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Feb 12, 2024
From: BIOPHARMA CREDIT PLC
To: IMMUNOGEN, INC.; IMMUNOGEN SWITZERLAND GMBH
Reel/Frame 066553/0109 →
PATENT SECURITY AGREEMENT Recorded Apr 6, 2023
From: IMMUNOGEN, INC.; IMMUNOGEN SWITZERLAND GMBH
To: BIOPHARMA CREDIT PLC
Reel/Frame 063282/0894 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2017
From: CARRIGAN, CHRISTINA N.; AB, OLGA; TAVARES, DANIEL; WOLF, BENI B.
To: IMMUNOGEN, INC.
Reel/Frame 043036/0336 →
Continuity (5)
Division 14921596 · Oct 23, 2015
Division 14015653 · Aug 30, 2013
Provisional Application 61756254 · Jan 24, 2013
Provisional Application 61695791 · Aug 31, 2012
Related Publication 20180003715A1 · Jan 4, 2018